Stay updated on Rebastinib with Paclitaxel in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Rebastinib with Paclitaxel in Solid Tumors Clinical Trial page.

Latest updates to the Rebastinib with Paclitaxel in Solid Tumors Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content removal, particularly regarding a clinical study of rebastinib (DCC-2036) in combination with paclitaxel, including detailed inclusion and exclusion criteria. The revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference12%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to December 27, 2024.SummaryDifference0.6%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version (v2.14.3) and a new last update date of March 25, 2025, replacing the previous estimated dates and version.SummaryDifference0.5%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for the Help Desk.SummaryDifference1%
Stay in the know with updates to Rebastinib with Paclitaxel in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rebastinib with Paclitaxel in Solid Tumors Clinical Trial page.